Q-omics provides the consensus-scored ITGB5 profile across patient tissues and cancer cell-line models. ITGB5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ITGB5 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, ITGB5 protein abundance shows 24,541 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight ACC, HNSC, and BRCA as cancer lineages where ITGB5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ITGB5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ITGB5 survival associations across molecular data types. ITGB5 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ITGB5 RNA expression–survival associations across cancer types. High ITGB5 expression shows unfavorable associations in ACC, PAAD, LIHC, MESO and LGG, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ITGB5 RNA expression.
This table summarizes ITGB5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ITGB5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ITGB5 shows lower tumor expression in KICH and higher tumor expression in HNSC, COAD, LIHC, LUAD and STAD. The HNSC box plot shows higher ITGB5 RNA expression in tumor versus normal tissue (log2 FC = +1.453, t-test p < 0.001).
This table shows molecular features associated with ITGB5 in patient tissues and cancer cell lines. In patient samples, ITGB5 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, ITGB5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in CNS and BONE.
